SUMOylation of UBE2C facilitates hepatocellular carcinoma proliferation and invasion via the MAPK pathway

Key Points

• UBE2C expression and stability are enhanced through MYBL2 and SUMOylation, leading to increased hepatocellular carcinoma proliferation and invasion.
• MAPK pathway activation is a key mechanism through which UBE2C promotes tumor progression, representing a critical axis for therapeutic targeting.
• This study identifies a previously unknown oncogenic axis, indicating that targeting MYBL2/UBE2C could provide a new therapeutic approach for hepatocellular carcinoma.
• The findings highlight the importance of the oncogenic interactions in HCC, calling for further exploration of their therapeutic implications.

Abstract